Aili He

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wanhong Zhao, Jie Liu, Baiyan Wang et al. · Journal of Hematology & Oncology · 2018 · 526 citations · Full text

Immunology, Immunodominance, Immunotherapeutics +19

Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes

Dan Zhang, Rui Guo, Lei Lei et al. · Journal of Leukocyte Biology · 2020 · 302 citations · Full text

COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome

Dan Zhang, Rui Guo, Lei Lei et al. · 2020 · 146 citations · Full text

Acute Lung Injury, Inflammatory Lung Disease, Immunodeficiencies +23

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Wanhong Zhao, Baiyan Wang, Lijuan Chen et al. · Journal of Hematology & Oncology · 2022 · 139 citations · Full text

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang et al. · Frontiers of Medicine · 2019 · 106 citations

Inflammation, Autoimmune Disease, T-regulatory Cell +7